Target Name: CDCA7
NCBI ID: G83879
Review Report on CDCA7 Target / Biomarker Content of Review Report on CDCA7 Target / Biomarker
CDCA7
Other Name(s): Cell division cycle-associated protein 7 | CDCA7 variant 1 | OTTHUMP00000163139 | OTTHUMP00000163138 | JPO1 | CDCA7_HUMAN | Cell division cycle associated 7, transcript variant 1 | MGC34109 | CDCA7 variant 2 | C-Myc target JPO1 | Protein JPO1 | Cell division cycle associated protein 7 | c-Myc target JPO1 | FLJ14736 | OTTHUMP00000205095 | Cell division cycle-associated protein 7 (isoform 2) | Cell division cycle-associated protein 7 (isoform 1) | ICF3 | cell division cycle associated 7 | Cell division cycle associated 7, transcript variant 2 | FLJ14722 | OTTHUMP00000205094

CDCA7: A Promising Drug Target and Biomarker for Cell Division Cycle-Associated Protein 7

Introduction

Cell division cycle-associated protein 7 (CDCA7) is a key regulator of the cell division cycle that controls the proper separation of chromosomes during cell division. CDCA7 has been identified as a potential drug target and biomarker for various diseases, including cancer. In this article, we will discuss the biology of CDCA7, its functions in cell division, and its potential as a drug target.

CDCA7: A KeyRegulator of Cell Division

CDCA7 is a 21-kDa protein that is expressed in most tissues of the body. It is a key regulator of the cell division cycle and is involved in the proper separation of chromosomes during cell division. CDCA7 plays a critical role in preventing errors that can occurs during DNA replication, such as errors in the number or structure of chromosomes.

CDCA7 is a transcription factor that interacts with DNA to regulate gene expression. It contains three domains: a N-terminal domain that contains a nuclear localization signal, a middle domain that contains a structural protein-coding region, and a C-terminal domain that contains a zinc finger domain. The N-terminal domain is responsible for the nuclear localization of CDCA7, while the middle domain contains the protein-coding region.

CDCA7 functions as a negative regulator of the cell division cycle. It inhibits the G1 phase of the cell division cycle by preventing the entry of RNA polymerase II into the nucleus. This inhibition prevents the initiation of the S-phase, which is the stage of DNA replication.

CDCA7 also functions as an oncogene. Its functions as a drug target have been attributed to its involvement in various diseases, including cancer. CDCA7 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers.

CDCA7 as a Biomarker

CDCA7 has also been used as a biomarker for various diseases. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. This increase in CDCA7 expression has been associated with the development and progression of these diseases.

CDCA7 has also been used as a biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that CDCA7 is overexpressed in the brains of individuals with these conditions, and that its levels are correlated with the severity of the diseases.

CDCA7 as a Drug Target

CDCA7 has been identified as a potential drug target for various diseases, including cancer. Its functions as a negative regulator of the cell division cycle and as an oncogene make it an attractive target for small molecules.

One of the most promising small molecules for CDCA7 is a compound called 2-fluorouracil (2FU). 2FU is an inhibitor of the DNA replication complex, which includes CDCA7. By inhibiting the function of CDCA7, 2FU has been shown to inhibit the growth and spread of various cancer cells.

Another small molecule that has been shown to be a potential CDCA7 inhibitor is 6-fluorouracil (6FU). 6FU is an inhibitor of the topoisomerase I, which is a key enzyme involved in the replication of DNA. By inhibiting the function of This enzyme, 6FU has been shown to inhibit the growth and spread of various cancer cells.

Conclusion

CDCA7 is a key regulator of the cell division cycle that plays a critical role in the proper separation of chromosomes during cell division. Its functions as a negative regulator of the cell division cycle and as an oncogene make it an attractive target for small molecules. Studies have shown that CDCA7 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers, and that its levels are associated with the development and progression of these diseases. Additionally, CDCA7 has also been used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and Alzheimer's and Parkinson's diseases. Therefore, CDCA7 is a promising drug target and biomarker for the development of new treatments for various diseases.

Protein Name: Cell Division Cycle Associated 7

Functions: Participates in MYC-mediated cell transformation and apoptosis; induces anchorage-independent growth and clonogenicity in lymphoblastoid cells. Insufficient to induce tumorigenicity when overexpressed but contributes to MYC-mediated tumorigenesis. May play a role as transcriptional regulator

The "CDCA7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDCA7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1